Woerwag R&D presentation Dec 2010

865 views
813 views

Published on

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
865
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Woerwag R&D presentation Dec 2010

  1. 1. Company ProfileWÖRWAG R&D GmbHWoerwag Research and Development GmbH, an independent subsidiary within the WörwagPharma Group: we are dedicated to develop generic and OTC products as well as other added valueproducts (e. g. new application forms, diagnostic devices) according to european guidelines.Our Mission: the right product right in time for launch upon patent expiry and for the right markets.Our professional and enthusiastic team is realising the mission to develop a range of generics andOTC-Products in up-to-date quality and meeting all regulatory, quality and IP requirements.On the following pages, you can find our current developments and the readily compiled dossierswith regulatory approval!Please visit us on the Internet: www.woerwag-rd.comDec 2010 I Wörwag R&D I Business Development I Dr. Wolfgang Bäurle www.woerwag-rd.com 1
  2. 2. Company ProfileWÖRWAG R&D GmbHReadily Compiled Dossiers:The following dossiers are readily compiled and have received german and some european MarketingAuthorisations. They are ready for submission in additional markets:•Clopidogrel film coated tablets (75 mg); Original: Plavix, Iscover•Enalapril-HCT tablets (20/12,5 mg); Original: Benalapril Plus•HCT tablets (12,5 | 25 mg); Original: Esidrix•Lagosa film coated tablets (Milk Thistle Dry Extract, corresponding to 150 mg Silymarin (UV))•Lagosa capsules (Milk Thistle Dry Extract, corresponding to 86,5 mg Silymarin (HPLC))•Losartan film coated tablets (12,5 | 25 | 50 | 100 mg); Original: Lorzaar•Losartan-HCT film coated tablets (50/12,5 | 100/12,5 | 100/25 mg); Original: Lorzaar Plus•Torasemid tablets (2,5 | 5 | 10 | 20 | 200 mg); Original: Torem, Unat•Xipamid tablets (10 | 20 | 40 mg); Original: AquaphorDec 2010 I Wörwag R&D I Business Development I Dr. Wolfgang Bäurle www.woerwag-rd.com 2
  3. 3. Company ProfileWÖRWAG R&D GmbH Current developments Currently we are developping the following products: •Candesartan tablets (2 | 4 | 8 | 16 | 32 mg), Dossier ready, DCP ongoing; Original: Atacand •Candesartan-HCT tablets (8/12,5 | 16/12,5 | 32/12,5 | 32/25 mg), Dossier ready until Q III-2011, DCP in Q IV- 2011; Original: Atacand Plus •Donepezil film coated tablets (5 | 10 mg), Dossier ready, DCP ongoing, Original: Aricept •Galantamine xr capsules (8 | 16 | 24 mg), Dossier ready in Dec. 2010, DCP in Jan. 2011; Original: Reminyl •Levetiracetam film coated tablets (250 | 500 | 750 | 1000 mg), Dossier ready, DCP ongoing, Original: Keppra •Pioglitazon tablets (15 | 30 | 45 mg), Dossier ready, DCP ongoing, Original: Actos •Valsartan tablets (40 | 80 | 160 | 320 mg), Dossier ready, DCP ongoing, Original: DiovanDec 2010 I Wörwag R&D I Business Development I Dr. Wolfgang Bäurle www.woerwag-rd.com 3
  4. 4. Company ProfileWÖRWAG R&D GmbH Contact: Wörwag R & D GmbH Calwer Str. 7 D-71034 Böblingen Germany Dr. Wolfgang Bäurle Head, Business Development Tel.: +49 7031-6204-794 Fax: +49 7031-6204-72 E-mail: Wolfgang.Baeurle@woerwagpharma.com Internet: www.woerwag-rd.comDec 2010 I Wörwag R&D I Business Development I Dr. Wolfgang Bäurle www.woerwag-rd.com 4

×